$Eli Lilly(LLY.US) +5% premarket after the drugmaker posted 2Q sales ahead of expectations on the strength of its obesity drugs and raised FY’26 revenue full-year forecast above expectations. Foundayo revs (weight loss pill) launched in June beat expectations.

FY’2026 guidance:

- Sees Revs $85.0B to $87.0B, saw $82.0B to $85.0B, vs $85.31B est.

- Sees Adj EPS $35.50 to $36.50, saw $35.50 to $37 vs $33.56 est.

2Q results:

- Adj EPS $8.38 +32% Y/Y vs. $6.37 est

- Revs $22.97 billion, +48% y/y, vs $20.59 estimate

- Mounjaro revenue $9.94B vs $8.83B est

- Zepbound revenue $4.93B vs $4.64B

- Foundayo revenue $98M vs $92M est

- Trulicity revenue $1.22B vs $869M est

- Verzenio rev. $1.47B, -1% y/y, vs $1.5B est

- Taltz rev. $856M vs $854.7M est

- R&D expenses $3.82B vs $4.05B est